Cytokinetics to Present at March Investor Conferences
28 February 2017 - 8:00AM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present a corporate update at the following investor conferences:
- Cowen and Company 37th Annual Health
Care Conference on Monday, March 6,
2017 at 2:00 PM EST at the Boston Marriott
Copley Place Hotel in Boston, MA
- 29th Annual ROTH
Conference on Monday, March 13,
2017 at 2:00 PM PST at the Ritz-Carlton, Laguna
Niguel in Dana Point, CA
Interested parties may access the live webcast of
this presentation by visiting the Investors & Media section of
the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal troponin activator
(FSTA). Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by
the European Medicines Agency. Cytokinetics is
preparing for the potential commercialization
of tirasemtiv in North
America and Europe and has granted an option
to Astellas Pharma Inc for development and
commercialization in other countries. Cytokinetics is
collaborating with Astellas to develop CK-2127107, a
next-generation fast skeletal muscle activator. CK-2127107 is
the subject of two ongoing Phase 2 clinical trials enrolling
patients with spinal muscular atrophy and chronic obstructive
pulmonary disease. Cytokinetics is collaborating
with Amgen Inc. to develop omecamtiv mecarbil, a
novel cardiac muscle activator. Omecamtiv mecarbil is the
subject of GALACTIC-HF, an international Phase 3 clinical trial in
patients with heart failure. Amgen holds an exclusive
worldwide license to develop and commercialize omecamtiv
mecarbil with a sublicense held by Servier for
commercialization in Europe and certain other countries.
Astellas holds an exclusive worldwide license to develop and
commercialize CK-2127107. Licenses held by Amgen and
Astellas are subject to Cytokinetics' specified
co-development and co-commercialization rights. For additional
information about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act’s safe harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to planned
presentations, and the properties and potential benefits of
Cytokinetics’ drug candidates and potential drug candidates. Such
statements are based on management’s current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory
approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and
that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024